Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 51 Show results per page	View Search Criteria \| Help With Results


1.		A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Supportive care				Completed				65 and under				Pharmaceutical / Industry				20-03-001 NCT00106392

Last Modified: 7/11/2007 First Published: 2/1/2000


2.		Phase II/III Randomized Study of Processed Versus Unprocessed Unrelated Bone Marrow Transplantation in Patients With Acute or Chronic Leukemia or Myelodysplastic Syndromes

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Supportive care, Treatment				Completed				12 to 50				Other				CHIMERIC-HM01 WSU-10-02-99-M01-FB, NCT00004255

Last Modified: 7/11/2007


3.		Phase III Randomized Study of FK506 vs CYSP as GVHD Prophylaxis Following Allogeneic Bone Marrow Transplantation (Summary Last Modified 05/94)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care				Closed				12 and over								WSU-Z-1093-93 NCI-V94-0363

Last Modified: 7/11/2007


4.		Phase III Randomized Study of FK506 vs CYSP as GVHD Prophylaxis Following Allogeneic Bone Marrow Transplantation (Summary Last Modified 05/97)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care				Closed				12 and over				Other				FHCRC-949.00 NCI-V95-0776

Last Modified: 7/11/2007


5.		Phase III Randomized Study of Filgrastim for Enhancement After Allogeneic Peripheral Blood Apheresis Cell Transplantation (PBACT) (Summary Last Modified 12/98)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				16 to 55				NCI				MDA-DM-94106 NCI-G96-1008

Last Modified: 10/29/2007 First Published: 3/1/2002


6.		Phase III Randomized Study of Prednisone and Cyclosporine With Versus Without Hydroxychloroquine in Patients With Newly Diagnosed Extensive Chronic Graft-Versus-Host Disease

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care				Completed				1 to 29				NCI				COG-ASCT0031 CCG-S9701, NCI-P02-0213, ASCT0031, NCT00031824

Last Modified: 11/20/2008 First Published: 11/1/2002


7.		Phase III Randomized Study of Daunorubicin and Cytarabine With or Without Gemtuzumab Ozogamicin Followed By Autologous Hematopoietic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia (Autologous Transplantation Arm II Closed to Accrual as of 10/4/2007)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				16 to 60				NCI				ECOG-1900 E1900, NCT00049517

Last Modified: 10/21/2008 First Published: 7/23/2004


8.		Phase III Randomized Study of Prednisone and Cyclosporine or Tacrolimus With Versus Without Mycophenolate Mofetil in Patients With Newly Diagnosed Chronic Graft-Versus-Host Disease

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care				Closed				4 and over				NCI				FHCRC-1697.00 5332, ROCHE-FHCRC-1697.00, NCT00089141, UMN-2004UC007

Last Modified: 1/1/2009 First Published: 3/16/2007


9.		Phase III Randomized Study of Filgrastim (G-CSF)-Stimulated Allogeneic Bone Marrow Transplantation Versus Conventional Bone Marrow Transplantation in Pediatric Patients With Hematologic Cancer or Other Diseases

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Temporarily closed				Under 22				NCI				COG-ASCT0631 ASCT0631, COG-PBMTC-STC051, NCT00450450

Last Modified: 7/1/2000


10.		Phase I/II Study of Chemotherapy with High-Dose Decitabine, Busulfan, and Cyclophosphamide with Allogeneic Stem Cell Transplantation in Patients With Hematologic Malignancies (Summary Last Modified 07/2000)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				15 to 55				NCI				MDA-DM-94064 NCI-G96-0999, NCT00002831

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute